CD133, CD44, and ALDH1A1 as cancer stem cell markers and prognostic factors in epithelial ovarian cancer

BACKGROUND Ovarian cancer is a heterogeneous disease, and most patients are diagnosed at an advanced stage. Epithelial ovarian cancer type II is characterized by rapid tumor growth and is genetically more labile than type I. This study was aimed to demonstrate the prognostic value of CSC by using th...

Full description

Saved in:
Bibliographic Details
Published in:Medical journal of Indonesia 2019-03, Vol.28 (1), p.63-9
Main Authors: Pelupessy, Nugraha Utama, Andrijono, Andrijono, Sutrisna, Bambang, Harahap, Alida Roswita, Kanoko, Mpu, Nuranna, Laila, Siregar, Budiningsih, Wulandari, Dewi
Format: Article
Language:English
Subjects:
Chemotherapy
Medical prognosis
Ovarian cancer
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c269t-2b634a3c917b9431505da6bdbf2be740337600ab6d7c8f0e8631742dcc8d06863
cites cdi_FETCH-LOGICAL-c269t-2b634a3c917b9431505da6bdbf2be740337600ab6d7c8f0e8631742dcc8d06863
container_end_page 9
container_issue 1
container_start_page 63
container_title Medical journal of Indonesia
container_volume 28
creator Pelupessy, Nugraha Utama
Andrijono, Andrijono
Sutrisna, Bambang
Harahap, Alida Roswita
Kanoko, Mpu
Nuranna, Laila
Siregar, Budiningsih
Wulandari, Dewi
description BACKGROUND Ovarian cancer is a heterogeneous disease, and most patients are diagnosed at an advanced stage. Epithelial ovarian cancer type II is characterized by rapid tumor growth and is genetically more labile than type I. This study was aimed to demonstrate the prognostic value of CSC by using the markers CD133, CD44, and ALDH1A1 in EOC.METHODS Clinicopathological and demographic data were collected from medical records. The markers CD133, CD44, and ALDH1A1 were examined with flow cytometry and immunohistochemistry. Cancer stem cell (CSC) marker expression in patients with ovarian cancer types I and II were related to chemotherapy and survival. In multivariate analysis, the prognosis model was tested for ten months.RESULTS The largest demographic consisted of patients aged ≥45 years, with stage I, poor differentiation, and type II, of which there were 40 samples (72.7%), 23 samples (41.8%), 30 samples (54.5%), and 16 samples (29.1%), respectively. There is a high correlation between the 10-month chemotherapy response and the 4 variables, i.e., age ≥45 years, type II, stage III–IV, and CD44, with an ROC of 80.75% and a post-test probability of 82.5%. Using the ROC curve, the highest chemoresistance score was 0.841, based on the combination of CSCs markers and clinicopathological factors, that is stage III–IV, age ≥45 years, poor differentiation, type II, negative CD133, high CD44, and high ALDH1A1.CONCLUSIONS CSC (CD133, CD44, and ALDH1A1) markers and clinicopathological factors are prognostic of epithelial ovarian cancer.
doi_str_mv 10.13181/mji.v28i1.2863
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2694942080</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2694942080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c269t-2b634a3c917b9431505da6bdbf2be740337600ab6d7c8f0e8631742dcc8d06863</originalsourceid><addsrcrecordid>eNotkDFPwzAQhS0EElXpzGqJtWltn2M7Y5UCRYrEArPlOA51SZNip5X495i20-lOT-_d-xB6pGRBgSq63O_84sSUpwumBNygCWM5yxRRcIsmROWQUSnhHs1i9DWhoIjIGZugbbmmAHNcrjmfY9M3eFWtN3RFsYnYmt66gOPo9ti6rsN7E75diGfdIQxf_RBHb3Fr7Diks--xO_hx6zpvOjycTPCmv7o8oLvWdNHNrnOKPl-eP8pNVr2_vpWrKrNMFGPGagHcgC2orAsONCd5Y0Td1C2rneQEQApCTC0aaVVLXCpLJWeNtaohIm1T9HTxTf_9HF0c9W44hj5F6hTAC86IIkm1vKhsGGIMrtWH4FO7X02JPhPViag-E9X_ROEPWKlnhQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2694942080</pqid></control><display><type>article</type><title>CD133, CD44, and ALDH1A1 as cancer stem cell markers and prognostic factors in epithelial ovarian cancer</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><creator>Pelupessy, Nugraha Utama ; Andrijono, Andrijono ; Sutrisna, Bambang ; Harahap, Alida Roswita ; Kanoko, Mpu ; Nuranna, Laila ; Siregar, Budiningsih ; Wulandari, Dewi</creator><creatorcontrib>Pelupessy, Nugraha Utama ; Andrijono, Andrijono ; Sutrisna, Bambang ; Harahap, Alida Roswita ; Kanoko, Mpu ; Nuranna, Laila ; Siregar, Budiningsih ; Wulandari, Dewi</creatorcontrib><description>BACKGROUND Ovarian cancer is a heterogeneous disease, and most patients are diagnosed at an advanced stage. Epithelial ovarian cancer type II is characterized by rapid tumor growth and is genetically more labile than type I. This study was aimed to demonstrate the prognostic value of CSC by using the markers CD133, CD44, and ALDH1A1 in EOC.METHODS Clinicopathological and demographic data were collected from medical records. The markers CD133, CD44, and ALDH1A1 were examined with flow cytometry and immunohistochemistry. Cancer stem cell (CSC) marker expression in patients with ovarian cancer types I and II were related to chemotherapy and survival. In multivariate analysis, the prognosis model was tested for ten months.RESULTS The largest demographic consisted of patients aged ≥45 years, with stage I, poor differentiation, and type II, of which there were 40 samples (72.7%), 23 samples (41.8%), 30 samples (54.5%), and 16 samples (29.1%), respectively. There is a high correlation between the 10-month chemotherapy response and the 4 variables, i.e., age ≥45 years, type II, stage III–IV, and CD44, with an ROC of 80.75% and a post-test probability of 82.5%. Using the ROC curve, the highest chemoresistance score was 0.841, based on the combination of CSCs markers and clinicopathological factors, that is stage III–IV, age ≥45 years, poor differentiation, type II, negative CD133, high CD44, and high ALDH1A1.CONCLUSIONS CSC (CD133, CD44, and ALDH1A1) markers and clinicopathological factors are prognostic of epithelial ovarian cancer.</description><identifier>ISSN: 0853-1773</identifier><identifier>EISSN: 2252-8083</identifier><identifier>DOI: 10.13181/mji.v28i1.2863</identifier><language>eng</language><publisher>Jakarta: Faculty of Medicine Universitas Indonesia</publisher><subject>Chemotherapy ; Medical prognosis ; Ovarian cancer ; Stem cells</subject><ispartof>Medical journal of Indonesia, 2019-03, Vol.28 (1), p.63-9</ispartof><rights>2019. This work is licensed under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c269t-2b634a3c917b9431505da6bdbf2be740337600ab6d7c8f0e8631742dcc8d06863</citedby><cites>FETCH-LOGICAL-c269t-2b634a3c917b9431505da6bdbf2be740337600ab6d7c8f0e8631742dcc8d06863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2694942080?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590</link.rule.ids></links><search><creatorcontrib>Pelupessy, Nugraha Utama</creatorcontrib><creatorcontrib>Andrijono, Andrijono</creatorcontrib><creatorcontrib>Sutrisna, Bambang</creatorcontrib><creatorcontrib>Harahap, Alida Roswita</creatorcontrib><creatorcontrib>Kanoko, Mpu</creatorcontrib><creatorcontrib>Nuranna, Laila</creatorcontrib><creatorcontrib>Siregar, Budiningsih</creatorcontrib><creatorcontrib>Wulandari, Dewi</creatorcontrib><title>CD133, CD44, and ALDH1A1 as cancer stem cell markers and prognostic factors in epithelial ovarian cancer</title><title>Medical journal of Indonesia</title><description>BACKGROUND Ovarian cancer is a heterogeneous disease, and most patients are diagnosed at an advanced stage. Epithelial ovarian cancer type II is characterized by rapid tumor growth and is genetically more labile than type I. This study was aimed to demonstrate the prognostic value of CSC by using the markers CD133, CD44, and ALDH1A1 in EOC.METHODS Clinicopathological and demographic data were collected from medical records. The markers CD133, CD44, and ALDH1A1 were examined with flow cytometry and immunohistochemistry. Cancer stem cell (CSC) marker expression in patients with ovarian cancer types I and II were related to chemotherapy and survival. In multivariate analysis, the prognosis model was tested for ten months.RESULTS The largest demographic consisted of patients aged ≥45 years, with stage I, poor differentiation, and type II, of which there were 40 samples (72.7%), 23 samples (41.8%), 30 samples (54.5%), and 16 samples (29.1%), respectively. There is a high correlation between the 10-month chemotherapy response and the 4 variables, i.e., age ≥45 years, type II, stage III–IV, and CD44, with an ROC of 80.75% and a post-test probability of 82.5%. Using the ROC curve, the highest chemoresistance score was 0.841, based on the combination of CSCs markers and clinicopathological factors, that is stage III–IV, age ≥45 years, poor differentiation, type II, negative CD133, high CD44, and high ALDH1A1.CONCLUSIONS CSC (CD133, CD44, and ALDH1A1) markers and clinicopathological factors are prognostic of epithelial ovarian cancer.</description><subject>Chemotherapy</subject><subject>Medical prognosis</subject><subject>Ovarian cancer</subject><subject>Stem cells</subject><issn>0853-1773</issn><issn>2252-8083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNotkDFPwzAQhS0EElXpzGqJtWltn2M7Y5UCRYrEArPlOA51SZNip5X495i20-lOT-_d-xB6pGRBgSq63O_84sSUpwumBNygCWM5yxRRcIsmROWQUSnhHs1i9DWhoIjIGZugbbmmAHNcrjmfY9M3eFWtN3RFsYnYmt66gOPo9ti6rsN7E75diGfdIQxf_RBHb3Fr7Diks--xO_hx6zpvOjycTPCmv7o8oLvWdNHNrnOKPl-eP8pNVr2_vpWrKrNMFGPGagHcgC2orAsONCd5Y0Td1C2rneQEQApCTC0aaVVLXCpLJWeNtaohIm1T9HTxTf_9HF0c9W44hj5F6hTAC86IIkm1vKhsGGIMrtWH4FO7X02JPhPViag-E9X_ROEPWKlnhQ</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Pelupessy, Nugraha Utama</creator><creator>Andrijono, Andrijono</creator><creator>Sutrisna, Bambang</creator><creator>Harahap, Alida Roswita</creator><creator>Kanoko, Mpu</creator><creator>Nuranna, Laila</creator><creator>Siregar, Budiningsih</creator><creator>Wulandari, Dewi</creator><general>Faculty of Medicine Universitas Indonesia</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BVBZV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20190301</creationdate><title>CD133, CD44, and ALDH1A1 as cancer stem cell markers and prognostic factors in epithelial ovarian cancer</title><author>Pelupessy, Nugraha Utama ; Andrijono, Andrijono ; Sutrisna, Bambang ; Harahap, Alida Roswita ; Kanoko, Mpu ; Nuranna, Laila ; Siregar, Budiningsih ; Wulandari, Dewi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c269t-2b634a3c917b9431505da6bdbf2be740337600ab6d7c8f0e8631742dcc8d06863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Chemotherapy</topic><topic>Medical prognosis</topic><topic>Ovarian cancer</topic><topic>Stem cells</topic><toplevel>online_resources</toplevel><creatorcontrib>Pelupessy, Nugraha Utama</creatorcontrib><creatorcontrib>Andrijono, Andrijono</creatorcontrib><creatorcontrib>Sutrisna, Bambang</creatorcontrib><creatorcontrib>Harahap, Alida Roswita</creatorcontrib><creatorcontrib>Kanoko, Mpu</creatorcontrib><creatorcontrib>Nuranna, Laila</creatorcontrib><creatorcontrib>Siregar, Budiningsih</creatorcontrib><creatorcontrib>Wulandari, Dewi</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>East &amp; South Asia Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Medical journal of Indonesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pelupessy, Nugraha Utama</au><au>Andrijono, Andrijono</au><au>Sutrisna, Bambang</au><au>Harahap, Alida Roswita</au><au>Kanoko, Mpu</au><au>Nuranna, Laila</au><au>Siregar, Budiningsih</au><au>Wulandari, Dewi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD133, CD44, and ALDH1A1 as cancer stem cell markers and prognostic factors in epithelial ovarian cancer</atitle><jtitle>Medical journal of Indonesia</jtitle><date>2019-03-01</date><risdate>2019</risdate><volume>28</volume><issue>1</issue><spage>63</spage><epage>9</epage><pages>63-9</pages><issn>0853-1773</issn><eissn>2252-8083</eissn><abstract>BACKGROUND Ovarian cancer is a heterogeneous disease, and most patients are diagnosed at an advanced stage. Epithelial ovarian cancer type II is characterized by rapid tumor growth and is genetically more labile than type I. This study was aimed to demonstrate the prognostic value of CSC by using the markers CD133, CD44, and ALDH1A1 in EOC.METHODS Clinicopathological and demographic data were collected from medical records. The markers CD133, CD44, and ALDH1A1 were examined with flow cytometry and immunohistochemistry. Cancer stem cell (CSC) marker expression in patients with ovarian cancer types I and II were related to chemotherapy and survival. In multivariate analysis, the prognosis model was tested for ten months.RESULTS The largest demographic consisted of patients aged ≥45 years, with stage I, poor differentiation, and type II, of which there were 40 samples (72.7%), 23 samples (41.8%), 30 samples (54.5%), and 16 samples (29.1%), respectively. There is a high correlation between the 10-month chemotherapy response and the 4 variables, i.e., age ≥45 years, type II, stage III–IV, and CD44, with an ROC of 80.75% and a post-test probability of 82.5%. Using the ROC curve, the highest chemoresistance score was 0.841, based on the combination of CSCs markers and clinicopathological factors, that is stage III–IV, age ≥45 years, poor differentiation, type II, negative CD133, high CD44, and high ALDH1A1.CONCLUSIONS CSC (CD133, CD44, and ALDH1A1) markers and clinicopathological factors are prognostic of epithelial ovarian cancer.</abstract><cop>Jakarta</cop><pub>Faculty of Medicine Universitas Indonesia</pub><doi>10.13181/mji.v28i1.2863</doi><tpages>-53</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0853-1773
ispartof Medical journal of Indonesia, 2019-03, Vol.28 (1), p.63-9
issn 0853-1773
2252-8083
language eng
recordid cdi_proquest_journals_2694942080
source Publicly Available Content Database (Proquest) (PQ_SDU_P3)
subjects Chemotherapy
Medical prognosis
Ovarian cancer
Stem cells
title CD133, CD44, and ALDH1A1 as cancer stem cell markers and prognostic factors in epithelial ovarian cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T10%3A32%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD133,%20CD44,%20and%20ALDH1A1%20as%20cancer%20stem%20cell%20markers%20and%20prognostic%20factors%20in%20epithelial%20ovarian%20cancer&rft.jtitle=Medical%20journal%20of%20Indonesia&rft.au=Pelupessy,%20Nugraha%20Utama&rft.date=2019-03-01&rft.volume=28&rft.issue=1&rft.spage=63&rft.epage=9&rft.pages=63-9&rft.issn=0853-1773&rft.eissn=2252-8083&rft_id=info:doi/10.13181/mji.v28i1.2863&rft_dat=%3Cproquest_cross%3E2694942080%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c269t-2b634a3c917b9431505da6bdbf2be740337600ab6d7c8f0e8631742dcc8d06863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2694942080&rft_id=info:pmid/&rfr_iscdi=true